{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:44:13Z","timestamp":1740109453415,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008070","name":"Department of Medicine, University of California, San Francisco","doi-asserted-by":"publisher","award":["RAP Award"],"award-info":[{"award-number":["RAP Award"]}],"id":[{"id":"10.13039\/100008070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA249744"],"award-info":[{"award-number":["K08CA249744"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","award":["ASCO Conquer Cancer Foundation Career Development Award"],"award-info":[{"award-number":["ASCO Conquer Cancer Foundation Career Development Award"]}],"id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00259-023-06296-z","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T04:01:47Z","timestamp":1686369707000},"page":"3349-3353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypoxia-specific imaging in patients with lymphoma undergoing CAR-T therapy"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiung-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divita","family":"Pandita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle K.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siobhan","family":"LaRue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyun Z.","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bita","family":"Fakhri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Spinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhav Rao","family":"Seshadri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Hernandez","family":"Pampaloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalambos Babis","family":"Andreadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,10]]},"reference":[{"issue":"26","key":"6296_CR1","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"10254","key":"6296_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet"},{"issue":"22","key":"6296_CR3","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D\u2019Aveni-Piney M, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(22):5607\u201315.","journal-title":"Blood Adv"},{"issue":"19","key":"6296_CR4","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(19):4898\u2013911.","journal-title":"Blood Adv"},{"issue":"14","key":"6296_CR5","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","volume":"4","author":"EA Dean","year":"2020","unstructured":"Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(14):3268\u201376.","journal-title":"Blood Adv"},{"issue":"19","key":"6296_CR6","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021;137(19):2621\u201333.","journal-title":"Blood"},{"issue":"5","key":"6296_CR7","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3109\/10428194.2012.733874","volume":"54","author":"MA Hernandez-Luna","year":"2013","unstructured":"Hernandez-Luna MA, Rocha-Zavaleta L, Vega MI, Huerta-Yepez S. Hypoxia inducible factor-1alpha induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-xL. Leuk Lymphoma. 2013;54(5):1048\u201355.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"6296_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/leu.2014.324","volume":"29","author":"J Chiche","year":"2015","unstructured":"Chiche J, Pommier S, Beneteau M, Mondragon L, Meynet O, Zunino B, et al. GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin\u2019s B lymphomas via NF-kappaB-dependent induction of HIF-1alpha. Leukemia. 2015;29(5):1163\u201376.","journal-title":"Leukemia"},{"issue":"1","key":"6296_CR9","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41598-018-19182-8","volume":"8","author":"K Bhalla","year":"2018","unstructured":"Bhalla K, Jaber S, Nahid MN, Underwood K, Beheshti A, Landon A, et al. Role of hypoxia in diffuse large B-cell lymphoma: metabolic repression and selective translation of HK2 facilitates development of DLBCL. Sci Rep. 2018;8(1):744.","journal-title":"Sci Rep"},{"key":"6296_CR10","doi-asserted-by":"crossref","unstructured":"Lukashev D, Klebanov B, Kojima H, Grinberg A, Ohta A, Berenfeld L, et al. Cutting edge: hypoxia-inducible factor 1 and its activation-inducible short isoform I.1 Negatively Regulate Functions of CD4+ and CD8+ T Lymphocytes. J Immunol. 2006;177(8):4962\u20135.","DOI":"10.4049\/jimmunol.177.8.4962"},{"issue":"5","key":"6296_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 2016;24(5):657\u201371.","journal-title":"Cell Metab"},{"issue":"4","key":"6296_CR12","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1159\/000464429","volume":"41","author":"AM Westendorf","year":"2017","unstructured":"Westendorf AM, Skibbe K, Adamczyk A, Buer J, Geffers R, Hansen W, et al. Hypoxia enhances immunosuppression by inhibiting CD4+ effector T cell function and promoting Treg activity. Cell Physiol Biochem. 2017;41(4):1271\u201384.","journal-title":"Cell Physiol Biochem"},{"issue":"11","key":"6296_CR13","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1172\/JCI96268","volume":"128","author":"P Jayaprakash","year":"2018","unstructured":"Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J, et al. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J Clin Invest. 2018;128(11):5137\u201349.","journal-title":"J Clin Invest"},{"key":"6296_CR14","doi-asserted-by":"publisher","unstructured":"Berahovich R, Liu X, Zhou H, Tsadik E, Xu S, Golubovskaya V, et al. Hypoxia selectively impairs CAR-T cells in vitro. Cancers (Basel). 2019;11(5): 602. https:\/\/doi.org\/10.3390\/cancers11050602","DOI":"10.3390\/cancers11050602"},{"key":"6296_CR15","doi-asserted-by":"crossref","unstructured":"Ando Y, Siegler EL, Ta HP, Cinay GE, Zhou H, Gorrell KA, et al. Evaluating CAR-T cell therapy in a hypoxic 3D tumor model. Adv Healthc Mater. 2019:e1900001.","DOI":"10.1002\/adhm.201900001"},{"issue":"19","key":"6296_CR16","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-10-1206","volume":"16","author":"EE Graves","year":"2010","unstructured":"Graves EE, Vilalta M, Cecic IK, Erler JT, Tran PT, Felsher D, et al. Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin Cancer Res. 2010;16(19):4843\u201352.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"6296_CR17","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.2174\/0929867324666171116123702","volume":"25","author":"N Quartuccio","year":"2018","unstructured":"Quartuccio N, Asselin M-C. The validation path of hypoxia PET imaging: focus on brain tumors. Curr Med Chem. 2018;25(26):3074\u201395.","journal-title":"Curr Med Chem"},{"issue":"10","key":"6296_CR18","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00259-009-1154-5","volume":"36","author":"EJ Postema","year":"2009","unstructured":"Postema EJ, McEwan AJ, Riauka TA, Kumar P, Richmond DA, Abrams DN, et al. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging. 2009;36(10):1565\u201373.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"6296_CR19","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2967\/jnumed.113.122671","volume":"58","author":"A Savi","year":"2017","unstructured":"Savi A, Incerti E, Fallanca F, Bettinardi V, Rossetti F, Monterisi C, et al. First evaluation of PET-based human biodistribution and dosimetry of (18)F-FAZA, a tracer for imaging tumor hypoxia. J Nucl Med. 2017;58(8):1224\u20139.","journal-title":"J Nucl Med"},{"issue":"1","key":"6296_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.radonc.2012.09.015","volume":"105","author":"LS Mortensen","year":"2012","unstructured":"Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET\/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol. 2012;105(1):14\u201320.","journal-title":"Radiother Oncol"},{"issue":"11","key":"6296_CR21","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1111\/cas.12771","volume":"106","author":"T Saga","year":"2015","unstructured":"Saga T, Inubushi M, Koizumi M, Yoshikawa K, Zhang MR, Tanimoto K, et al. Prognostic value of (18) F-fluoroazomycin arabinoside PET\/CT in patients with advanced non-small-cell lung cancer. Cancer Sci. 2015;106(11):1554\u201360.","journal-title":"Cancer Sci"},{"issue":"8","key":"6296_CR22","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1007\/s00259-014-2730-x","volume":"41","author":"S Servagi-Vernat","year":"2014","unstructured":"Servagi-Vernat S, Differding S, Hanin F, Labar D, Bol A, Lee JA, et al. A prospective clinical study of 18F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. Eur J Nucl Med Mol Imaging. 2014;41(8):1544\u201352.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"6296_CR23","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2967\/jnumed.112.115014","volume":"54","author":"VR Bollineni","year":"2013","unstructured":"Bollineni VR, Kerner GS, Pruim J, Steenbakkers RJ, Wiegman EM, Koole MJ, et al. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients. J Nucl Med. 2013;54(8):1175\u201380.","journal-title":"J Nucl Med"},{"issue":"1","key":"6296_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2174\/1874471010666171108162319","volume":"11","author":"P Mapelli","year":"2018","unstructured":"Mapelli P, Bettinardi V, Fallanca F, Incerti E, Compierchio A, Rossetti F, et al. 18F-FAZA PET\/CT in the preoperative evaluation of NSCLC: comparison with 18F-FDG and immunohistochemistry. Curr Radiopharm. 2018;11(1):50\u20137.","journal-title":"Curr Radiopharm"},{"issue":"2","key":"6296_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.radonc.2014.10.010","volume":"113","author":"VR Bollineni","year":"2014","unstructured":"Bollineni VR, Koole MJ, Pruim J, Brouwer CL, Wiegman EM, Groen HJ, et al. Dynamics of tumor hypoxia assessed by 18F-FAZA PET\/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies. Radiother Oncol. 2014;113(2):198\u2013203.","journal-title":"Radiother Oncol"},{"key":"6296_CR26","doi-asserted-by":"crossref","unstructured":"Bruine de Bruin L, Bollineni VR, Wachters JE, Schuuring E, van Hemel BM, van der Wal JE, et al. Assessment of hypoxic subvolumes in laryngeal cancer with (18)F-fluoroazomycinarabinoside ((18)F-FAZA)-PET\/CT scanning and immunohistochemistry. Radiother Oncol. 2015;117(1):106\u201312.","DOI":"10.1016\/j.radonc.2015.07.012"},{"issue":"7","key":"6296_CR27","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2021.0168","volume":"7","author":"F Hauth","year":"2021","unstructured":"Hauth F, Ho AY, Ferrone S, Duda DG. Radiotherapy to enhance chimeric antigen receptor T-cell therapeutic efficacy in solid tumors: a narrative review. JAMA Oncol. 2021;7(7):1051\u20139.","journal-title":"JAMA Oncol"},{"key":"6296_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.813832","volume":"12","author":"VM Qin","year":"2021","unstructured":"Qin VM, Haynes NM, D\u2019Souza C, Neeson PJ, Zhu JJ. CAR-T plus radiotherapy: a promising combination for immunosuppressive tumors. Front Immunol. 2021;12: 813832.","journal-title":"Front Immunol"},{"issue":"2","key":"6296_CR29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2):380\u201390.","journal-title":"Immunity"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06296-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06296-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06296-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T07:03:04Z","timestamp":1695970984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06296-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,10]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["6296"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06296-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"type":"print","value":"1619-7070"},{"type":"electronic","value":"1619-7089"}],"subject":[],"published":{"date-parts":[[2023,6,10]]},"assertion":[{"value":"24 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Our study was reviewed and approved by the University of California San Francisco Institutional Review Board. Informed consent was obtained from all individual participants included in the study. The authors affirm that human research participants provided informed consent for the publication of the images in Fig.\u00a0.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"RB: Consulting: BMS, Caribou Biosciences, Genentech, Janssen, Pfizer, Sanofi, SparkCures; research support: Pack Health. VW: Research support: Inhibrx. WZA: Consulting: Kite, ADC, More Health, Secura Bio, Kyowa. BF: Consulting: Abbvie, Adaptive, AstraZeneca, BeiGene, BMS, CurioScience, Genentech, Genmab, Loxo\/Lilly, Medscape, Pharmacyclics, TG Therapeutics; Research support: Abbvie, BMS, Genmab, Loxo\/Lilly. MS: Consulting: Gilead, Kite. MRS: Consulting: Beigene, Gilead; research support: Eli Lilly, Roche. CA: Consulting: BMS, Gilead; Research support: BMS, Novartis. Remaining authors: none.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}